Display options
Cite
Hertlein L, Rath J, Zeder-Göss C, et al. Coexistence of adenomyosis uteri and endometrial cancer is associated with an improved prognosis compared with endometrial cancer only. Oncol Lett. 2017;14(3):3302-3308doi: 10.3892/ol.2017.6592.
Hertlein, L., Rath, J., Zeder-Göss, C., Fürst, S., Bayer, D., Trillsch, F., Mahner, S., Burges, A., & Jeschke, U. (2017). Coexistence of adenomyosis uteri and endometrial cancer is associated with an improved prognosis compared with endometrial cancer only. Oncology letters, 14(3), 3302-3308. https://doi.org/10.3892/ol.2017.6592
Hertlein, Linda, et al. "Coexistence of adenomyosis uteri and endometrial cancer is associated with an improved prognosis compared with endometrial cancer only." Oncology letters vol. 14,3 (2017): 3302-3308. doi: https://doi.org/10.3892/ol.2017.6592
Hertlein L, Rath J, Zeder-Göss C, Fürst S, Bayer D, Trillsch F, Mahner S, Burges A, Jeschke U. Coexistence of adenomyosis uteri and endometrial cancer is associated with an improved prognosis compared with endometrial cancer only. Oncol Lett. 2017 Sep;14(3):3302-3308. doi: 10.3892/ol.2017.6592. Epub 2017 Jul 18. PMID: 28927080; PMCID: PMC5588003.
Copy Download .nbib Format: NLM
Share it on

Oncol Lett. 2017 Sep;14(3):3302-3308. doi: 10.3892/ol.2017.6592. Epub 2017 Jul 18.

Coexistence of adenomyosis uteri and endometrial cancer is associated with an improved prognosis compared with endometrial cancer only.

Oncology letters

Linda Hertlein, Johanna Rath, Christine Zeder-Göss, Sophie Fürst, Daniela Bayer, Fabian Trillsch, Sven Mahner, Alexander Burges, Udo Jeschke

Affiliations

  1. Department of Obstetrics and Gynecology, Ludwig-Maximilian University of Munich, D-81377 Munich, Germany.

PMID: 28927080 PMCID: PMC5588003 DOI: 10.3892/ol.2017.6592

Abstract

The present study aimed to identify differences in protein expression in cases of endometrioid endometrial cancer (EEC) with and without coexisting adenomyosis uteri (AM), and to evaluate the histopathological and prognostic distinctions. The total cohort included 22 patients in Group A (patients with concomitant AM and EEC) and 35 patients in Group B (patients affected only by EEC). Evaluation of the following factors was performed: Tumour grade, International Federation of Gynaecology and Obstetrics (FIGO) stage, survival, and expression of estrogen receptor β (ERβ), glycodelin and inhibin βB. Group A (AM and EEC) was associated with a lower tumour grade (G1, 90.9 vs. 45.7%; P=0.001) and a lower FIGO stage (FIGO stage I, 100 vs. 80%; P=0.002) compared with Group B (EEC only). In the survival analysis, Group A was associated with a significantly higher 5-year survival rate (95 vs. 82%; P=0.024) than Group B. In addition, the expression of ERβ in Group A was significantly higher (P<0.001), whereas the expression of glycodelin is significantly lower (P=0.028), compared with Group B. The results of the present study indicate that the presence of AM in cases of EEC may be a positive prognostic factor.

Keywords: adenomyosis uteri; endometrioid endometrial cancer; estrogen receptor β; glycodelin; inhibin βB

References

  1. Recent Prog Horm Res. 1988;44:1-34 - PubMed
  2. Ann Surg Oncol. 2016 Mar;23 (3):959-67 - PubMed
  3. Zentralbl Gynakol. 2003 Oct;125(10):415-23 - PubMed
  4. Hum Pathol. 2004 Jun;35(6):649-62 - PubMed
  5. Ann Diagn Pathol. 2007 Aug;11(4):252-7 - PubMed
  6. Fertil Steril. 2011 Jun;95(7):2228-35, 2235.e1 - PubMed
  7. Hum Reprod Update. 2015 Mar-Apr;21(2):174-93 - PubMed
  8. Histochem Cell Biol. 2009 Feb;131(2):283-95 - PubMed
  9. Arch Gynecol Obstet. 2003 Aug;268(3):142-50 - PubMed
  10. Gynecol Oncol. 2004 Apr;93(1):9-13 - PubMed
  11. Mol Hum Reprod. 1999 Jul;5(7):651-5 - PubMed
  12. Menopause. 2001 Summer;8(2):149-50 - PubMed
  13. Anticancer Res. 2007 Jul-Aug;27(4A):2011-7 - PubMed
  14. Acta Histochem. 2004;106(3):245-52 - PubMed
  15. Proc Natl Acad Sci U S A. 2001 Jul 31;98 (16):9265-70 - PubMed
  16. Oncol Lett. 2016 Feb;11(2):1213-1219 - PubMed
  17. Int J Cancer. 2004 Jul 20;110(6):783-7 - PubMed
  18. Semin Reprod Endocrinol. 1999;17(3):257-65 - PubMed
  19. Anticancer Res. 2005 May-Jun;25(3A):1581-9 - PubMed
  20. Best Pract Res Clin Obstet Gynaecol. 2006 Aug;20(4):511-21 - PubMed
  21. Pathologe. 1987 May;8(3):138-40 - PubMed
  22. Ann Surg Oncol. 2014 Dec;21(13):4246-55 - PubMed
  23. Am J Obstet Gynecol. 2012 Nov;207(5):417.e1-6 - PubMed
  24. Int J Radiat Oncol Biol Phys. 1991 Sep;21(4):1027-32 - PubMed
  25. Gynecol Oncol. 2012 Dec;127(3):673-6 - PubMed
  26. Eur J Cancer. 2007 Nov;43(16):2434-44 - PubMed
  27. Cancer Invest. 2004;22(2):211-8 - PubMed
  28. Eur J Gynaecol Oncol. 1995;16(1):18-25 - PubMed
  29. Anticancer Res. 2005 May-Jun;25(3A):1679-86 - PubMed
  30. J Clin Endocrinol Metab. 1981 May;52(5):1006-8 - PubMed
  31. Endocrinology. 2003 Jul;144(7):2870-81 - PubMed
  32. Gynecol Endocrinol. 2015;31(8):613-7 - PubMed
  33. Acta Histochem. 2006;108(1):1-11 - PubMed
  34. Histopathology. 2006 Mar;48(4):394-406 - PubMed
  35. Eur J Gynaecol Oncol. 2011;32(2):182-4 - PubMed
  36. Gynecol Oncol. 2014 Jun;133(3):512-7 - PubMed
  37. Fertil Steril. 2003 Sep;80 Suppl 2:820-7 - PubMed
  38. Mol Cell Endocrinol. 2009 Mar 25;301(1-2):74-82 - PubMed
  39. Semin Reprod Med. 2012 Jan;30(1):39-45 - PubMed
  40. BMC Cancer. 2013 Dec 30;13:616 - PubMed
  41. Int J Gynecol Pathol. 1996 Jul;15(3):217-21 - PubMed
  42. Cancer Detect Prev. 2004;28(2):94-8 - PubMed
  43. Histochem Cell Biol. 2000 Nov;114(5):405-11 - PubMed
  44. CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30 - PubMed
  45. Pathologe. 2011 May;32(3):239-43 - PubMed

Publication Types